Global Drug Intermediate Market Overview: 2023-2029


Global Drug Intermediate Market is expected to reach US$ 60.85 Bn. at a CAGR of 4.98 during the forecast period 2029.

Drug intermediates are used as raw materials during the manufacture of bulk drugs. These intermediates can also be referred to as the material produced at the time of synthesis of an active pharmaceutical ingredient (API).

The report covers the current estimate and forecast for drug intermediate market on a global and regional level. The report provides an in-depth analysis of the drug intermediate market for the period 2023-2029, wherein 2012 is the base year and the period from 2023 to 2029 is the forecast period. Data for 2018-2022 has been included as historical information. The study provides a detail perspective on market growth, throughout the above forecast period in terms of revenue estimates (in US$ MN), across different geographies, which includes North America (NA), Europe (EU), Asia Pacific (APAC), Middle East & Africa (MEA) and Latin America (LATAM).

Drug Intermediate MarketTo Know About The Research Methodology :- Request Free Sample Report

The report provides qualitative and quantitative insights on the drug intermediate market trends and detail analysis of market size and growth rate of all segment in the market. The global drug intermediate market is segmented by Type, End User and Region.

Some of the prominent brands in the global drug intermediate market include Ami Lifesciences, Accrete Pharmaceuticals Pvt. Ltd, A.B. Enterprises, Ramdev Chemicals Pvt. Ltd., Clearsynth, Aarti Drugs Ltd., Synpure Labs and Karvy Therapeutics Pvt. Ltd, among others.

Global Drug Intermediate Market Dynamics

Bio-production is becoming more popular as a way to produce safer and more effective drugs. New and creative methods for curing cancer, cystic fibrosis, asthma, blindness and heart disease are now showing the lucrative opportunities for the global drug intermediate market growth. Increasing requirements for drug intermediates in the international market for the rapid developments and advancements happening in the life sciences and biotechnology fields. Growing adoption and rising applications of drug intermediates in the field of research and clinical studies is the driving factor for the global market.

Companies operating in the pharmaceutical and biotechnology sectors along with research institutes are now increasingly focusing on R&D activities relating to drug creation and development. They are also paying special attention to creating new techniques and methods along with equipment for the synthesis of drug intermediates. In the future, this will offer manufacturers the flexibility to provide high levels of customisation in synthesised drugs. Increasing scope of broad ranging applications of drug intermediates has thus helped in the overall development of the global drug intermediates market.

Global presence of API manufacturers help to make global drug intermediate markets outlook positive.

The growing trend toward new high-tech therapeutics, coupled with the emergence of novel and innovative delivery systems and the evolution of personalized medicines, will only serve to further emphasize the growing demand for advanced APIs. The demand for drugs intermediates to treat the aging population will definitely boost the sales of active pharmaceutical ingredients that are popularly used for manufacturing drug products.

Companies operating in the pharmaceutical industry can make use of these drug intermediates for the purposes of R&D.

In the early years the sole players in the global drug intermediate market were multinationals such as Glaxo, Pfizer, and Parke-Davis. Global pharmaceutical companies both imported and manufactured drug intermediates for various kinds of drug formulations. The pharma sector undergoing with the emergence of new domestic companies, which drive the global drug intermediate market.

Advantages for domestic healthcare industry included the availability of skilled scientific personnel, the low cost of raw material, production, labour and government policy that supported indigenous production of drug intermediates in the private small-scale pharma industry sector.

The speed at which new product technologies were adopted and the ability of Indian companies to develop cost-effective processes and effective distribution systems grow the global drug intermediate market in the forecast period.

Asia Pacific to dominate the global drug intermediate market.

Global Drug Intermediate Market 1The greatest concentrations of API and drug intermediate manufacturers are located around Asia, specifically in India and China. Due to a growing pool of geriatrics in Asia Pacific, this region is primarily driving the global drug intermediate market. Improving access to health care and the growing demand for pharmaceuticals in Asia-Pacific and the rest of the world are likely to create lucrative growth opportunities for the overall market.

Unsustainable cost structures, stakeholders’ push for value as well as an increased sophistication in health care systems to cope with more robust data and risk mitigation approaches, governments across the globe are shifting their focus from volume-based to value-based health care services as a way of reducing spending while improving outcomes. With an ageing population and the rise of chronic diseases within the Asia Pacific region, the need for such interventions has create the opportunity for growth of global drug intermediate market.

Scope of the Drug Intermediate Market: Inquire before buying






Drug Intermediate Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 43.30 Bn.




Forecast Period 2023 to 2029 CAGR:
4.98%
Market Size in 2029:
US $ 60.85 Bn.




 Segments Covered:
by Type
API Intermediate
Advance Intermediate




by End User
Pharmaceutical Industry
Biotechnology Industry
Clinical Industry






Drug Intermediate Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

Key Players Operated in Global Drug Intermediate Market

1. Ami Lifesciences
2. Accrete Pharmaceuticals Pvt. Ltd
3. A.B. Enterprises
4. Ramdev Chemicals Pvt. Ltd.
5. Clearsynth
6. Aarti Drugs Ltd.
7. Synpure Labs
8. Karvy Therapeutics Pvt. Ltd
9. Glaxo
10.Pfizer,
11.Parke-Davis

Frequently Asked Questions:

1. What is the market size of the Global Drug Intermediate Market in 2022?
Ans. The market size Global Diagnostic Speciality Enzymes Market in 2022 was US$ 43.30 Billion

2.What is the growth rate of Global Drug Intermediate Market?
Ans: The Global Drug Intermediate Market is growing at a CAGR of 4.98 % during forecasting period 2023-2029.

3.What is scope of the Global Drug Intermediate Market report?
Ans: Global Drug Intermediate Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors& Leaders, and market estimation of the forecast period.

4.Who are the key players in Global Drug Intermediate Market?
Ans: The important key players in the Global Drug Intermediate Market are – Denso Corporation, Hanon Systems, Sanden Holding Corporation, Mitsubishi Heavy Industries Ltd, MAHLE GmbH, Valeo SA, Keihin Corporation, Calsonic Kansei Corporation, SamvardhanaMotherson Group, Subros Limited, SMAC Auto Air, TransAir Manufacturing, Eberspacher Group, Marelli Corporation.

5.What is the study period of this Market?
Ans: The Global Drug Intermediate Market is studied from 2022 to 2029. 





Global Drug Intermediate Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Drug Intermediate Market Size, By Market Value (US$ Mn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Global Drug Intermediate Market Analysis and Forecast
6.1. Drug Intermediate Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Drug Intermediate Market Analysis and Forecast, By Type
7.1. Introduction and Definition
7.2. Key Findings
7.3. Drug Intermediate Market Value Share Analysis, By Type
7.4. Drug Intermediate Market Size (US$ Mn) Forecast, By Type
7.5. Drug Intermediate Market Analysis, By Type
7.6. Drug Intermediate Market Attractiveness Analysis, By Type

8. Global Drug Intermediate Market Analysis and Forecast, By End User
8.1. Introduction and Definition
8.2. Key Findings
8.3. Drug Intermediate Market Value Share Analysis, By End User
8.4. Drug Intermediate Market Size (US$ Mn) Forecast, By End User
8.5. Drug Intermediate Market Analysis, By End User
8.6. Drug Intermediate Market Attractiveness Analysis, By End User

9. Global Drug Intermediate Market Analysis, By Region
9.1. Drug Intermediate Market Value Share Analysis, By Region
9.2. Drug Intermediate Market Size (US$ Mn) Forecast, By Region
9.3. Drug Intermediate Market Attractiveness Analysis, By Region

10. North America Drug Intermediate Market Analysis
10.1. Key Findings
10.2. North America Drug Intermediate Market Overview
10.3. North America Drug Intermediate Market Value Share Analysis, By Type
10.4. North America Drug Intermediate Market Forecast, By Type
10.4.1. API Intermediate
10.4.2. Advance Intermediate
10.5. North America Drug Intermediate Market Value Share Analysis, By End User
10.6. North America Drug Intermediate Market Forecast, By End User
10.6.1. Pharmaceutical Industry
10.6.2. Biotechnology Industry
10.6.3. Clinical Industry
10.7. North America Drug Intermediate Market Value Share Analysis, By Country
10.8. North America Drug Intermediate Market Forecast, By Country
10.8.1. U.S.
10.8.2. Canada
10.8.3. Mexico
10.9. North America Drug Intermediate Market Analysis, By Country
10.10. U.S. Drug Intermediate Market Forecast, By Type
10.10.1. API Intermediate
10.10.2. Advance Intermediate
10.11. U.S. Drug Intermediate Market Forecast, By End User
10.11.1. Pharmaceutical Industry
10.11.2. Biotechnology Industry
10.11.3. Clinical Industry
10.12. Canada Drug Intermediate Market Forecast, By Type
10.12.1. API Intermediate
10.12.2. Advance Intermediate
10.13. Canada Drug Intermediate Market Forecast, By End User
10.13.1. Pharmaceutical Industry
10.13.2. Biotechnology Industry
10.13.3. Clinical Industry
10.14. Mexico Drug Intermediate Market Forecast, By Type
10.14.1. API Intermediate
10.14.2. Advance Intermediate
10.15. Mexico Drug Intermediate Market Forecast, By End User
10.15.1. Pharmaceutical Industry
10.15.2. Biotechnology Industry
10.15.3. Clinical Industry
10.16. North America Drug Intermediate Market Attractiveness Analysis
10.16.1. By Type
10.16.2. By End User
10.17. PEST Analysis
10.18. Key Trends
10.19. Key Developments

11. Europe Drug Intermediate Market Analysis
11.1. Key Findings
11.2. Europe Drug Intermediate Market Overview
11.3. Europe Drug Intermediate Market Value Share Analysis, By Type
11.4. Europe Drug Intermediate Market Forecast, By Type
11.4.1. API Intermediate
11.4.2. Advance Intermediate
11.5. Europe Drug Intermediate Market Value Share Analysis, By End User
11.6. Europe Drug Intermediate Market Forecast, By End User
11.6.1. Pharmaceutical Industry
11.6.2. Biotechnology Industry
11.6.3. Clinical Industry
11.7. Europe Drug Intermediate Market Value Share Analysis, By Country
11.8. Europe Drug Intermediate Market Forecast, By Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Sweden
11.8.7. CIS countries
11.8.8. Rest of Europe
11.9. Germany Drug Intermediate Market Forecast, By Type
11.9.1. API Intermediate
11.9.2. Advance Intermediate
11.10. Germany Drug Intermediate Market Forecast, By End User
11.10.1. Pharmaceutical Industry
11.10.2. Biotechnology Industry
11.10.3. Clinical Industry
11.11. U.K. Drug Intermediate Market Forecast, By Type
11.11.1. API Intermediate
11.11.2. Advance Intermediate
11.12. U.K. Drug Intermediate Market Forecast, By End User
11.12.1. Pharmaceutical Industry
11.12.2. Biotechnology Industry
11.12.3. Clinical Industry
11.13. France Drug Intermediate Market Forecast, By Type
11.13.1. API Intermediate
11.13.2. Advance Intermediate
11.14. France Drug Intermediate Market Forecast, By End User
11.14.1. Pharmaceutical Industry
11.14.2. Biotechnology Industry
11.14.3. Clinical Industry
11.15. Italy Drug Intermediate Market Forecast, By Type
11.15.1. API Intermediate
11.15.2. Advance Intermediate
11.16. Italy Drug Intermediate Market Forecast, By End User
11.16.1. Pharmaceutical Industry
11.16.2. Biotechnology Industry
11.16.3. Clinical Industry
11.17. Spain Drug Intermediate Market Forecast, By Type
11.17.1. API Intermediate
11.17.2. Advance Intermediate
11.18. Spain Drug Intermediate Market Forecast, By End User
11.18.1. Pharmaceutical Industry
11.18.2. Biotechnology Industry
11.18.3. Clinical Industry
11.19. Sweden Drug Intermediate Market Forecast, By Type
11.19.1. API Intermediate
11.19.2. Advance Intermediate
11.20. Sweden Drug Intermediate Market Forecast, By End User
11.20.1. Pharmaceutical Industry
11.20.2. Biotechnology Industry
11.20.3. Clinical Industry
11.21. CIS countries Drug Intermediate Market Forecast, By Type
11.21.1. API Intermediate
11.21.2. Advance Intermediate
11.22. CIS countries Drug Intermediate Market Forecast, By End User
11.22.1. Pharmaceutical Industry
11.22.2. Biotechnology Industry
11.22.3. Clinical Industry
11.23. Rest of Europe Drug Intermediate Market Forecast, By Type
11.23.1. API Intermediate
11.23.2. Advance Intermediate
11.24. Rest of Europe Drug Intermediate Market Forecast, By End User
11.24.1. Pharmaceutical Industry
11.24.2. Biotechnology Industry
11.24.3. Clinical Industry
11.25. Europe Drug Intermediate Market Attractiveness Analysis
11.25.1. By End User
11.25.2. By Type
11.26. PEST Analysis
11.27. Key Trends
11.28. Key Developments

12. Asia Pacific Drug Intermediate Market Analysis
12.1. Key Findings
12.2. Asia Pacific Drug Intermediate Market Overview
12.3. Asia Pacific Drug Intermediate Market Value Share Analysis, By Type
12.4. Asia Pacific Drug Intermediate Market Forecast, By Type
12.4.1. API Intermediate
12.4.2. Advance Intermediate
12.5. Asia Pacific Drug Intermediate Market Value Share Analysis, By End User
12.6. Asia Pacific Drug Intermediate Market Forecast, By End User
12.6.1. Pharmaceutical Industry
12.6.2. Biotechnology Industry
12.6.3. Clinical Industry
12.7. Asia Pacific Drug Intermediate Market Value Share Analysis, By Country
12.8. Asia Pacific Drug Intermediate Market Forecast, By Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. South Korea
12.8.5. Australia
12.8.6. ASEAN
12.8.7. Rest of Asia Pacific
12.9. Asia Pacific Drug Intermediate Market Analysis, By Country
12.10. China Drug Intermediate Market Forecast, By Type
12.10.1. API Intermediate
12.10.2. Advance Intermediate
12.11. China Drug Intermediate Market Forecast, By End User
12.11.1. Pharmaceutical Industry
12.11.2. Biotechnology Industry
12.11.3. Clinical Industry
12.12. India Drug Intermediate Market Forecast, By Type
12.12.1. API Intermediate
12.12.2. Advance Intermediate
12.13. India Drug Intermediate Market Forecast, By End User
12.13.1. Pharmaceutical Industry
12.13.2. Biotechnology Industry
12.13.3. Clinical Industry
12.14. Japan Drug Intermediate Market Forecast, By Type
12.14.1. API Intermediate
12.14.2. Advance Intermediate
12.15. Japan Drug Intermediate Market Forecast, By End User
12.15.1. Pharmaceutical Industry
12.15.2. Biotechnology Industry
12.15.3. Clinical Industry
12.16. South Korea Drug Intermediate Market Forecast, By Type
12.16.1. API Intermediate
12.16.2. Advance Intermediate
12.17. South Korea Drug Intermediate Market Forecast, By End User
12.17.1. Pharmaceutical Industry
12.17.2. Biotechnology Industry
12.17.3. Clinical Industry
12.18. Australia Drug Intermediate Market Forecast, By Type
12.18.1. API Intermediate
12.18.2. Advance Intermediate
12.19. Australia Drug Intermediate Market Forecast, By End User
12.19.1. Pharmaceutical Industry
12.19.2. Biotechnology Industry
12.19.3. Clinical Industry
12.20. ASEAN Drug Intermediate Market Forecast, By Type
12.20.1. API Intermediate
12.20.2. Advance Intermediate
12.21. ASEAN Drug Intermediate Market Forecast, By End User
12.21.1. Pharmaceutical Industry
12.21.2. Biotechnology Industry
12.21.3. Clinical Industry
12.22. Rest of Asia Pacific Drug Intermediate Market Forecast, By Type
12.22.1. API Intermediate
12.22.2. Advance Intermediate
12.23. Rest of Asia Pacific Drug Intermediate Market Forecast, By End User
12.23.1. Pharmaceutical Industry
12.23.2. Biotechnology Industry
12.23.3. Clinical Industry
12.24. Asia Pacific Drug Intermediate Market Attractiveness Analysis
12.24.1. By Type
12.24.2. By End User
12.25. PEST Analysis
12.26. Key Trends
12.27. Key Developments

13. Middle East & Africa Drug Intermediate Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Drug Intermediate Market Overview
13.3. Middle East & Africa Drug Intermediate Market Value Share Analysis, By Type
13.4. Middle East & Africa Drug Intermediate Market Forecast, By Type
13.4.1. API Intermediate
13.4.2. Advance Intermediate
13.5. Middle East & Africa Drug Intermediate Market Value Share Analysis, By End User
13.6. Middle East & Africa Drug Intermediate Market Forecast, By End User
13.6.1. Pharmaceutical Industry
13.6.2. Biotechnology Industry
13.6.3. Clinical Industry
13.7. Middle East & Africa Drug Intermediate Market Value Share Analysis, By Country
13.8. Middle East & Africa Drug Intermediate Market Forecast, By Country
13.8.1. GCC Countries
13.8.2. South Africa
13.8.3. Nigeria
13.8.4. Egypt
13.8.5. Rest of Middle East & Africa
13.9. Middle East & Africa Drug Intermediate Market Analysis, By Country
13.10. GCC Countries Drug Intermediate Market Forecast, By Type
13.10.1. API Intermediate
13.10.2. Advance Intermediate
13.11. GCC Countries Drug Intermediate Market Forecast, By End User
13.11.1. Pharmaceutical Industry
13.11.2. Biotechnology Industry
13.11.3. Clinical Industry
13.12. South Africa Drug Intermediate Market Forecast, By Type
13.12.1. API Intermediate
13.12.2. Advance Intermediate
13.13. South Africa Drug Intermediate Market Forecast, By End User
13.13.1. Pharmaceutical Industry
13.13.2. Biotechnology Industry
13.13.3. Clinical Industry
13.14. Nigeria Drug Intermediate Market Forecast, By Type
13.14.1. API Intermediate
13.14.2. Advance Intermediate
13.15. Nigeria Drug Intermediate Market Forecast, By End User
13.15.1. Pharmaceutical Industry
13.15.2. Biotechnology Industry
13.15.3. Clinical Industry
13.16. Egypt Drug Intermediate Market Forecast, By Type
13.16.1. API Intermediate
13.16.2. Advance Intermediate
13.17. Egypt Drug Intermediate Market Forecast, By End User
13.17.1. Pharmaceutical Industry
13.17.2. Biotechnology Industry
13.17.3. Clinical Industry
13.18. Rest of Middle East & Africa Drug Intermediate Market Forecast, By Type
13.18.1. API Intermediate
13.18.2. Advance Intermediate
13.19. Rest of Middle East & Africa Drug Intermediate Market Forecast, By End User
13.19.1. Pharmaceutical Industry
13.19.2. Biotechnology Industry
13.19.3. Clinical Industry
13.20. Middle East & Africa Drug Intermediate Market Attractiveness Analysis
13.20.1. By Type
13.20.2. By End User
13.21. PEST Analysis
13.22. Key Trends
13.23. Key Developments

14. South America Drug Intermediate Market Analysis
14.1. Key Findings
14.2. South America Drug Intermediate Market Overview
14.3. South America Drug Intermediate Market Value Share Analysis, By Type
14.4. South America Drug Intermediate Market Forecast, By Type
14.4.1. API Intermediate
14.5. Advance Intermediate
14.6. South America Drug Intermediate Market Forecast, By End User
14.6.1. Pharmaceutical Industry
14.6.2. Biotechnology Industry
14.6.3. Clinical Industry
14.7. South America Drug Intermediate Market Value Share Analysis, By Country
14.8. South America Drug Intermediate Market Forecast, By Country
14.8.1. Brazil
14.8.2. Colombia
14.8.3. Argentina
14.8.4. Rest of South America
14.9. South America Drug Intermediate Market Analysis, By Country
14.10. Brazil Drug Intermediate Market Forecast, By Type
14.10.1. API Intermediate
14.10.2. Advance Intermediate
14.11. Brazil Drug Intermediate Market Forecast, By End User
14.11.1. Pharmaceutical Industry
14.11.2. Biotechnology Industry
14.11.3. Clinical Industry
14.12. Colombia Drug Intermediate Market Forecast, By Type
14.12.1. API Intermediate
14.12.2. Advance Intermediate
14.13. Colombia Drug Intermediate Market Forecast, By End User
14.13.1. Pharmaceutical Industry
14.13.2. Biotechnology Industry
14.13.3. Clinical Industry
14.14. Argentina Drug Intermediate Market Forecast, By Type
14.14.1. API Intermediate
14.14.2. Advance Intermediate
14.15. Argentina Drug Intermediate Market Forecast, By End User
14.15.1. Pharmaceutical Industry
14.15.2. Biotechnology Industry
14.15.3. Clinical Industry
14.16. Rest of South America Drug Intermediate Market Forecast, By Type
14.16.1. API Intermediate
14.16.2. Advance Intermediate
14.17. Rest of South America Drug Intermediate Market Forecast, By End User
14.17.1. Pharmaceutical Industry
14.17.2. Biotechnology Industry
14.17.3. Clinical Industry
14.18. South America Drug Intermediate Market Attractiveness Analysis
14.18.1. By Type
14.18.2. By End User
14.19. PEST Analysis
14.20. Key Trends
14.21. Key Developments

15. Company Profiles
15.1. Market Share Analysis, By Company
15.2. Competition Matrix

15.2.1. Competitive Benchmarking of key players By price, presence, market share, Component, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A By Regions, Investment and Component
15.2.3.2. M&A Key Players, Forward Integration and Backward Integration

15.3. Company Profiles: Key Players
15.3.1. Ami Lifesciences
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Development Footprint
15.3.2. Accrete Pharmaceuticals Pvt. Ltd
15.3.3. A.B. Enterprises
15.3.4. Ramdev Chemicals Pvt. Ltd.
15.3.5. Clearsynth
15.3.6. Aarti Drugs Ltd.
15.3.7. Synpure Labs
15.3.8. Karvy Therapeutics Pvt. Ltd
15.3.9. Glaxo
15.3.10. Pfizer
15.3.11. Parke-Davis

16. Primary key Insights
  • INQUIRE BEFORE BUYING